Different diabetes medications have very different side effect profiles: metformin commonly causes GI upset and can deplete vitamin B12 long-term; GLP-1 agonists like semaglutide and tirzepatide frequently cause nausea and vomiting and carry black box warnings for thyroid tumor risk; sulfonylureas like glipizide are the most likely to cause hypoglycemia; while DPP-4 inhibitors like sitagliptin are generally well tolerated.
Diabetes Medication Side Effects: Common, Serious & Long-Term
Diabetes medications span several distinct drug classes, each targeting different mechanisms of blood sugar regulation and carrying a different side effect profile. This guide covers the five most commonly prescribed agents: metformin, semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound), sitagliptin (Januvia), and glipizide (Glucotrol). Understanding which side effects belong to which drug helps patients and caregivers recognize what is expected and what requires attention.
Metformin: GI Upset, Lactic Acidosis, and B12 Depletion
Metformin is the most widely prescribed first-line medication for type 2 diabetes. It works primarily by reducing glucose production in the liver and improving insulin sensitivity. It does not cause weight gain and rarely causes hypoglycemia when used alone.
Common: GI Side Effects
Nausea, diarrhea, abdominal cramping, and an unpleasant metallic taste are the most frequent complaints with metformin, particularly when starting treatment or increasing the amount taken. These effects stem from metformin's impact on gut motility and the microbiome. They typically improve over the first few weeks. Taking metformin with food and starting at a lower amount that is increased gradually significantly reduces GI symptoms. Extended-release formulations generally produce fewer GI side effects than immediate-release.
Serious: Lactic Acidosis
Lactic acidosis — a dangerous buildup of lactic acid in the blood — is a rare but potentially fatal complication of metformin. It occurs most often in patients with conditions that reduce oxygen delivery or liver function: acute kidney injury, severe heart failure, respiratory failure, or excessive alcohol use. Metformin should be temporarily held before iodinated contrast procedures (such as CT scans with contrast) and in times of severe illness where fluid intake is reduced, as kidney function can deteriorate rapidly in these settings.
⚠ Symptoms of lactic acidosis include severe nausea and vomiting, rapid breathing, abdominal pain, weakness, and confusion. This is a medical emergency — seek emergency care immediately.
Long-Term: Vitamin B12 Deficiency
Metformin interferes with the absorption of vitamin B12 in the intestine by competing with a calcium-dependent absorption mechanism in the ileum. Over years of use, B12 levels can fall low enough to cause peripheral neuropathy (nerve damage with tingling and numbness in the hands and feet) or anemia. This is particularly concerning in patients who already have diabetes-related neuropathy, as the symptoms can overlap. Periodic B12 level monitoring is recommended for long-term metformin users.
GLP-1 Receptor Agonists: Semaglutide and Tirzepatide
Semaglutide (Ozempic for diabetes, Wegovy for weight management) and tirzepatide (Mounjaro for diabetes, Zepbound for weight management) are injectable medications that mimic gut hormones to lower blood sugar and reduce appetite. They have become among the most prescribed medications in the United States due to their blood sugar benefits and significant weight loss effects.
Common: Nausea, Vomiting, and GI Effects
GI side effects are by far the most common complaints with GLP-1 receptor agonists. Nausea is reported by a large proportion of users, especially when starting treatment or increasing to a higher amount. Vomiting, diarrhea, constipation, and stomach pain are also common. These effects result from slowed gastric emptying (gastroparesis-like effect) and direct GLP-1 receptor activity in the gut and brainstem.
For most patients, nausea improves significantly after the first few weeks. Eating smaller meals, avoiding high-fat or high-sugar foods, and not lying down immediately after eating can help manage GI symptoms during the adjustment period.
Serious: Pancreatitis
Both semaglutide and tirzepatide have been associated with acute pancreatitis. Patients should be aware of the symptoms: persistent severe abdominal pain (often radiating to the back), nausea, and vomiting. These medications should be discontinued if pancreatitis is confirmed and generally not restarted.
Delayed Gastric Emptying and Procedural Concerns
GLP-1 agonists slow the rate at which food leaves the stomach. This creates a risk during anesthesia or sedation: food retained in the stomach longer than expected can be aspirated into the lungs. Anesthesiologists increasingly recommend holding GLP-1 agonists before elective procedures. Discuss this with your surgical team and prescriber in advance of any planned procedure.
Sulfonylureas: Glipizide — Hypoglycemia and Weight Gain
Glipizide (Glucotrol) is a sulfonylurea — it stimulates the pancreas to release insulin regardless of current blood sugar levels. This makes it effective at lowering blood sugar but also means it carries a meaningful risk of hypoglycemia (dangerously low blood sugar), particularly if meals are skipped or delayed.
Common: Hypoglycemia
Hypoglycemia is the most important side effect of sulfonylureas. Symptoms include shakiness, sweating, dizziness, hunger, confusion, and in severe cases, loss of consciousness or seizures. The risk is higher in elderly patients, those with impaired kidney or liver function, and those who miss meals or exercise more than usual. Consuming a fast-acting carbohydrate (glucose tablets, juice) at the first signs of low blood sugar is essential.
Common: Weight Gain
Unlike metformin or GLP-1 agonists, sulfonylureas tend to cause modest weight gain over time. This is a result of increased insulin secretion and may partially offset the cardiovascular benefits of blood sugar control.
DPP-4 Inhibitors: Sitagliptin — Generally Well Tolerated
Sitagliptin (Januvia) belongs to the DPP-4 inhibitor class, which works by preventing the breakdown of incretin hormones, increasing insulin secretion in a glucose-dependent manner. Because sitagliptin only stimulates insulin when blood sugar is elevated, it rarely causes hypoglycemia when used alone.
Common Side Effects
DPP-4 inhibitors are among the best-tolerated diabetes medications. The most commonly reported side effects are nasopharyngitis (runny nose, sore throat) and mild upper respiratory tract infections. Joint pain (arthralgia) has been reported and may sometimes be severe.
Serious but Rare: Pancreatitis and Bullous Pemphigoid
Like GLP-1 agonists, sitagliptin has a rare association with pancreatitis. There is also a rare association with bullous pemphigoid, a blistering skin condition. These are uncommon but worth knowing for monitoring purposes.
Long-Term Effects Across Diabetes Medications
- Metformin: Gradual B12 depletion; periodic monitoring and supplementation may be needed after years of use
- GLP-1 agonists: Long-term thyroid monitoring is generally not required unless symptoms develop; ongoing GI tolerance usually improves; cardiovascular benefits have been demonstrated in long-term studies
- Sulfonylureas: Cumulative risk of hypoglycemic episodes; some studies suggest a possible decline in pancreatic beta-cell function over very long-term use; weight gain accumulates
- DPP-4 inhibitors: Long-term safety profile is generally favorable; some studies initially raised concerns about heart failure hospitalization with saxagliptin but this was not replicated consistently with sitagliptin
Who Is Most at Risk for Serious Side Effects
- Elderly patients on glipizide — highest hypoglycemia risk; confusion from low blood sugar can be mistaken for dementia
- Patients with chronic kidney disease — metformin may need to be held or avoided; some GLP-1 agonist adjustments may be needed
- Anyone with a history of pancreatitis — GLP-1 agonists and DPP-4 inhibitors should be used cautiously
- Patients with a personal or family history of MTC or MEN 2 — GLP-1 agonists are contraindicated
- Long-term metformin users — at risk for undetected B12 deficiency, especially if already experiencing neuropathy
Managing Diabetes Medication Side Effects
GI side effects from metformin and GLP-1 agonists improve significantly with food and slow dose escalation — do not stop these medications without speaking with your prescriber first, as blood sugar management is critical. Report signs of pancreatitis (severe abdominal pain), lactic acidosis (rapid breathing, confusion), or hypoglycemia (shakiness, sweating, confusion) to your healthcare team promptly.
Patients on GLP-1 agonists should alert their surgical or anesthesia team before any planned procedure. Long-term metformin users should ask their provider about periodic B12 testing. Patients on glipizide should always have fast-acting glucose available and should not skip meals.
Frequently Asked Questions
Why does metformin cause stomach upset and diarrhea?
Metformin affects the gut microbiome and increases intestinal serotonin release, which accelerates gut motility. GI side effects are most pronounced when starting metformin or increasing the amount. Taking it with food significantly reduces these effects. Extended-release formulations of metformin also tend to cause fewer GI side effects than immediate-release formulations.
What are the side effects of semaglutide (Ozempic, Wegovy)?
The most common semaglutide side effects are GI-related: nausea, vomiting, diarrhea, constipation, and stomach pain. These are most pronounced when starting or increasing the amount and often improve over several weeks. More serious but rare risks include pancreatitis and — based on animal studies — a possible thyroid C-cell tumor risk, which carries an FDA black box warning. Semaglutide is not recommended for people with a personal or family history of medullary thyroid carcinoma.
Which diabetes medications cause low blood sugar (hypoglycemia)?
Sulfonylureas like glipizide are the most likely oral diabetes medications to cause hypoglycemia, because they stimulate insulin release regardless of blood sugar levels. Metformin, GLP-1 receptor agonists (semaglutide, tirzepatide), and DPP-4 inhibitors (sitagliptin) have a low risk of hypoglycemia when used alone, though the risk increases when combined with sulfonylureas or insulin.
Can long-term metformin use cause vitamin B12 deficiency?
Yes. Metformin reduces vitamin B12 absorption from the gut by interfering with calcium-dependent uptake in the ileum. Deficiency develops gradually over years of use and may go unnoticed until it causes nerve damage (peripheral neuropathy) or anemia. Periodic B12 monitoring is recommended for long-term metformin users, and supplementation may be needed.
Related Drug Guides
⚠ This article is for informational purposes only and does not constitute medical advice. Never adjust or stop your diabetes medications without consulting your prescriber — blood sugar management requires individualized medical guidance.